Clinical trials versus clinical practice in the secondary prevention of myocardial infarction. 1994

A Agustí, and J M Arnau, and J R Laporte
Unitat de Farmacologia Clínica, Universitat Autònoma de Barcelona, CSU Vall d'Hebron, Spain.

To examine whether the results of trials on the secondary prevention of myocardial infarction have led to a change of prescription practice, the discharge forms of a random sample of 737 patients admitted to a university hospital with a diagnosis of acute myocardial infarction (MI) with Q wave from 1982 to 1988 were examined. Information about cardiovascular and other risk factors, contraindications, and prescription of beta-adrenoceptor antagonists (beta AA), acetylsalicylic acid (ASA) and calcium channel blockers (CCB) was collected. The prescription of these drugs was analysed in relation to clinical variables and the date of patients' discharge from hospital. During the 7 years of follow-up, the prescription of beta AA increased gradually from 20% to 30-35%; the prescription of CCB was above 30% during the same period and did not change significantly with time. The prescription of ASA increased from 0% to 30-35% in the last 3 years of follow-up. Contraindications to beta AA were present in 23.2% of cases and contraindications to ASA in 14.4%. In a multivariate analysis, hypertension (odds ratio 2.29, 95% confidence interval 1.55-3.38) and the period 1986-1988 (OR 2.27, 95% CI 1.57-3.30) were associated with the prescription of beta AA, although the prescription of beta AA decreased significantly with advancing age. Other variables inversely associated with the prescription of beta AA were contraindications (OR 0.41, 95% CI 0.24-0.66) and the presence of heart failure during admission (OR 0.08, 95% CI 0.03-0.20).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010818 Practice Patterns, Physicians' Patterns of practice related to diagnosis and treatment as especially influenced by cost of the service requested and provided. Clinical Practice Patterns,Physician's Practice Patterns,Clinical Practice Pattern,Pattern, Clinical Practice,Patterns, Clinical Practice,Practice Pattern, Clinical,Practice Patterns, Clinical,Practice Patterns, Physician's,Prescribing Patterns, Physician,Physician Practice Patterns,Physician Prescribing Pattern,Physician Prescribing Patterns,Physician's Practice Pattern,Physicians' Practice Pattern,Physicians' Practice Patterns,Practice Pattern, Physician's,Practice Pattern, Physicians',Practice Patterns, Physician,Prescribing Pattern, Physician
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004363 Drug Utilization The utilization of drugs as reported in individual hospital studies, FDA studies, marketing, or consumption, etc. This includes drug stockpiling, and patient drug profiles. Utilization, Drug,Drug Utilizations,Utilizations, Drug
D005260 Female Females
D006785 Hospitals, University Hospitals maintained by a university for the teaching of medical students, postgraduate training programs, and clinical research. University Hospitals
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Agustí, and J M Arnau, and J R Laporte
January 1995, European journal of clinical pharmacology,
A Agustí, and J M Arnau, and J R Laporte
February 1976, Thrombosis and haemostasis,
A Agustí, and J M Arnau, and J R Laporte
June 1980, Thrombosis and haemostasis,
A Agustí, and J M Arnau, and J R Laporte
January 1988, Journal of cardiovascular pharmacology,
A Agustí, and J M Arnau, and J R Laporte
July 1987, The American journal of cardiology,
A Agustí, and J M Arnau, and J R Laporte
January 1986, Acta medica Scandinavica. Supplementum,
A Agustí, and J M Arnau, and J R Laporte
March 2018, The British journal of general practice : the journal of the Royal College of General Practitioners,
A Agustí, and J M Arnau, and J R Laporte
January 1982, Progress in cardiovascular diseases,
A Agustí, and J M Arnau, and J R Laporte
October 1999, Current problems in cardiology,
A Agustí, and J M Arnau, and J R Laporte
May 2003, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!